Physicians' Academy for Cardiovascular Education

Lipids

Novel strategy of triple therapy with bempedoic acid, ezetimibe and statin

5' education - Apr. 8, 2021 - Prof. Stephen Nicholls, MD

Explained risk from apoB-containing lipoproteins to MI

5' education - Jan. 13, 2021 - Prof. Børge Nordestgaard, MD

Combination therapy to achieve lower LDL-c goals is the way forward

3' education - Oct. 27, 2020 - Prof. Kausik Ray, MD

Latest results with non-LDL lowering agents in reducing CV risk

10' education - Oct. 26, 2020 - Prof. Ulrich Laufs, MD

The role for primary care in reducing CV risk in diabetes

10' education - Oct. 20, 2020 - Prof. Richard Hobbs, MD - Online CME

A novel small binding protein that targets PCSK9

3' education - Oct. 6, 2020 - Prof. Evan Stein, MD, PhD

Updates in the 2019 ESC/EAS guidelines for the management of dyslipidemia

10' education - Sep. 29, 2020 - Prof. François Mach, MD

Burden of residual risk: Are triglycerides a risk marker?

10' education - Aug. 18, 2020 - Prof. Klaus Parhofer, MD

Familial Hypercholesterolemia: Why and how to screen?

10' education - June 30, 2020 - Prof. Kees Hovingh, MD, PhD

Addressing lipid risk: a system-wide approach to implementation

5' education - Feb. 27, 2020 - Jorge Plutzky, MD

Lipids beyond LDL-c: HDL-c and triglycerides

5' education - Feb. 25, 2020 - Prof. Peter Libby, MD

Patient-reported cognition at the end of a PCSK9 antibody trial

5' education - Nov. 17, 2019 - Baris Gencer, MD

Translating ESC/EAS Dyslipidemia Guidelines to clinical practice

10' education - Feb. 18, 2020 - Prof. Kausik Ray, MD

The mechanism of action of bempedoic acid

Feb. 2, 2020

Treatment benefit with PCSK9 antibody in patients with recent vs. remote MI

5' education - Feb. 2, 2020 - Baris Gencer, MD

Translating pathophysiological, genetic and trial data to practical LDL-c treatment recommendations

10' education - Dec. 19, 2019 - Professor Ulrich Laufs, MD, PhD

The safety of PCSK9 inhibitors - how low can we go?

5' education - Jan. 22, 2020 - Robert Giugliano, MD

Rationale of new recommendations in ESC/EAS Guidelines for Dyslipidemia

10' education - Dec. 19, 2019 - Prof. Ulf Landmesser, MD

The growing global challenge of CV risk

5' education - Jan. 15, 2020 - Thomas Gaziano, MD

LDL-c, atherosclerotic plaques and CV risk - what to do about it

10' education - Jan. 14, 2020 - Prof. Thomas Lüscher, MD

New tool can help identify FH patients

3' education - Nov. 17, 2019 - Willem Bax, Alkmaar - AHA 2019, Philadelphia

PCSK9 siRNA, on top of maximally tolerated statin therapy, potently lowers LDL-c

3' education - Nov. 16, 2019 - R. Scott Wright, MD, Rochester, MN, USA - AHA 2019, Philadelphia

Mechanisms of action of GLP-1RAs

10' education - Oct. 21, 2019 - Prof. Filip Knop, MD

A transatlantic discussion on the new LDL-c guidelines: What are the key differences?

10' education - Oct. 11, 2019 - Prof. Christie Ballantyne, MD

Extending the evidence: What did the FOURIER trial teach us on managing high-risk patients?

10' education - Sep. 24, 2019 - Prof. Marc S. Sabatine, MD

Targeting PCSK9: Expanding knowledge and targeting new frontiers

10' education - Sep. 24, 2019 - Paris, France - Prof. John Kastelein, MD

Reduced LDL-c with PCSK9 inhibitor in acute setting of ACS

5' education - Aug. 31, 2019 - Paris, France - Prof. François Mach

LDL-c lowering with twice-a-year injection of siRNA against PCSK9: The ORION-11 trial

10' education - Sep. 16, 2019 - Prof. John Kastelein

The 2019 ESC/EAS Dyslipidemia Guidelines from the point of view of the European Atherosclerosis Society

5' education - Sep. 12, 2019 - Prof. Alberico Catapano

Rationale for the lower LDL-c targets in the 2019 ESC/EAS Dyslipidemia Guidelines

5' education - Sep. 9, 2019 - Paris, France - Prof. François Mach

Sustained CV benefits of statin treatment after discontinuation

Literature - May 12, 2021 - Bosch J et al. - Eur Heart J. 2021

CV benefits of rosuvastatin, compared with placebo, are sustained or enhanced even after stopping therapy in individuals without CVD but at intermediate risk for CV events.

Novel strategy of triple therapy with bempedoic acid, ezetimibe and statin

5' education - Apr. 8, 2021 - Prof. Stephen Nicholls, MD
Prof. Stephen Nicholls discusses the results of a study that investigated the lipid-lowering effects of triple therapy with bempedoic acid, ezetimibe and statin as a new potential strategy for treating hypercholesterolemia.

Prof. Stephen Nicholls discusses the results of a study that investigated the lipid-lowering effects of triple therapy with bempedoic acid, ezetimibe and statin as a new potential strategy for treating hypercholesterolemia.

ApoB and non-HDL-c are better markers of residual risk than LDL-c in statin-treated patients

Literature - Apr. 7, 2021 - Johannesen CDL et al. - J Am Coll Cardiol. 2021

Elevated levels of apoB and non-HDL-c better reflect residual risk for all-cause mortality and MI than LDL-c levels in patients treated with statins.

Elevated Lp(a) associated with large artery atherosclerosis stroke and risk of recurrent stroke

Literature - Mar. 23, 2021 - Arnold M et al. - Eur Heart J. 2021

The prospective BIOSIGNAL cohort study showed that elevated Lp(a) was independently associated with LAA stroke etiology and risk of recurrent AIS or TIA in patients <60 years.

Elevated Lp(a) associated with CAD in individuals without a family history of CVD

Literature - Mar. 8, 2021 - Finneran P et al. - J Am Heart Assoc. 2021

This study investigated the risk of incident CAD in participants from the UK Biobank with and without a family history of CVD in a sibling or parent.

LDL-c lowering with triple therapy of statin, ezetimibe and bempedoic acid

Literature - Feb. 9, 2021 - Rubino J et al., - Atherosclerosis. 2020

This phase 2 randomized clinical trial showed that initiation of triple therapy with statin, ezetimibe and bempedoic acid significantly reduced LDL-c by 60.5%, compared with placebo.

U-shaped association between LDL-c levels and all cause mortality in the general population

Literature - Feb. 8, 2021 - Johannesen CDL et al., - BMJ. 2020

This study in a large, contemporary general population cohort showed that low and high LDL-c levels are associated with all cause mortality. LDL-c of 3.6 mmol/L (140 mg/dL) was associated with the lowest risk of all cause mortality.

Larger early LDL-c lowering after MI associated with reduced CV outcomes in real-world setting

Literature - Feb. 4, 2021 - Schubert J, et al. - Eur Heart J 2021

Large-scale observational data from the SWEDEHEART registry showed that in patients in clinical practice early and aggressive LDL-c lowering after MI was associated with reduced risk of major CV outcomes and mortality.

People aged 70-100 years with elevated LDL-c are at high risk of MI and ASCVD

Literature - Jan. 21, 2021 - Mortensen MB & Nordestgaard BG., - Lancet. 2020

In a contemporary primary prevention cohort, MI and ASCVD event rates increased with higher LDL-c and older age. NNT to prevent one MI or ASCVD event was lower in people aged 70-100 years compared to younger individuals.

Explained risk from apoB-containing lipoproteins to MI

5' education - Jan. 13, 2021 - Prof. Børge Nordestgaard, MD
A study using data from the Copenhagen General Population Study showed that cholesterol in VLDL explains 50% of the MI risk from apoB-containing lipoproteins. Triglycerides in VLDL explain 0%.

A study using data from the Copenhagen General Population Study showed that cholesterol in VLDL explains 50% of the MI risk from apoB-containing lipoproteins. Triglycerides in VLDL explain 0%. With poll.

E-learning The evolving role of triglyceride-rich lipoproteins

EBAC-accredited E-Learning

Online-CME - This course consists of 3 parts.
This course consists of 3 parts.

This educational program consists of three presentations on residual CVD risk with a focus on triglycerides and triglyceride-rich lipoproteins.

Combination therapy to achieve lower LDL-c goals is the way forward

3' education - Oct. 27, 2020 - Prof. Kausik Ray, MD
The DA VINCI study demonstrated that the majority of prescibed therapies for lipid-lowering in Europe is monotherapy with statins and only one-third of patients met their LDL-c goal described in the 2019 dyslipidemia guidelines.

The DA VINCI study demonstrated that the majority of prescibed therapies for lipid-lowering in Europe is monotherapy with statins and only one-third of patients met their LDL-c goal described in the 2019 dyslipidemia guidelines. With poll.